Avenue Therapeutics Set to Shine at Upcoming Healthcare Summit
MIAMI, Oct. 09, 2024 — Avenue Therapeutics, Inc. (Nasdaq: ATXI), a dedicated specialty pharmaceutical company, is gearing up for an impactful presence at the upcoming Maxim Group’s 2024 Healthcare Virtual Summit. On this important occasion, Alexandra MacLean, M.D., the Chief Executive Officer of Avenue Therapeutics, will engage in a compelling fireside chat designed to foster meaningful discussions around the company's role in advancing therapies for neurologic diseases.
Insightful Discussions on Neurologic Therapies
This engaging session will take place on Tuesday, October 15, and is set to provide valuable insights for registered attendees. Avenue Therapeutics has positioned itself as a pioneer in the development and commercialization of innovative treatments specifically aimed at neurologic conditions.
What to Expect from the Fireside Chat
During the discussion, Dr. MacLean is expected to elaborate on the company's strategic initiatives, including updates on their current projects and future aspirations. Avenue Therapeutics is committed to addressing unmet medical needs in neurologic conditions, ensuring they remain at the forefront of the industry.
Avenue Therapeutics' Innovative Portfolio
Currently, Avenue Therapeutics is advancing three notable assets that showcase its commitment to enhancing patient outcomes. Among these, AJ201 stands out as a first-in-class treatment intended for spinal and bulbar muscular atrophy. Another promising asset is BAER-101, an oral medication designed as a selective GABAA ?2, ?3 receptor positive allosteric modulator aimed at benefiting patients with various CNS disorders.
Focusing on Postoperative Pain Management
In addition to their impressive research pipeline, Avenue is also developing IV tramadol, which targets the management of acute postoperative pain in adults. This therapy is designed for use in medically supervised healthcare settings, ensuring that patients receive the highest level of care during recovery periods.
Company Background and Vision
Founded by Fortress Biotech, Inc. (Nasdaq: FBIO), Avenue Therapeutics is headquartered in Miami, Florida. The company’s mission is to bridge gaps in current treatment methodologies by offering state-of-the-art solutions for neurologic disorders. With a skilled team and strong vision, Avenue Therapeutics is poised to make a significant impact in the pharmaceutical landscape.
Contact Avenue Therapeutics for More Information
For those intrigued by Avenue Therapeutics’ mission or who wish to learn more about their innovative therapies, additional information is readily available on their official website. Moreover, questions can be directed to Jaclyn Jaffe at Avenue Therapeutics. She can be reached at (781) 652-4500 or via email.
Frequently Asked Questions
What is Avenue Therapeutics focused on?
Avenue Therapeutics focuses on developing and commercializing therapies for neurologic diseases.
Who will be speaking at the Maxim Group’s 2024 Healthcare Summit?
Alexandra MacLean, M.D., the CEO of Avenue Therapeutics, will participate in a fireside chat.
What are the key assets being developed by Avenue Therapeutics?
Key assets include AJ201, BAER-101, and IV tramadol aimed at treating various neurologic conditions.
How can investors attend the fireside chat?
Investors can sign up or log in as registered attendees for the healthcare summit.
Where is Avenue Therapeutics headquartered?
Avenue Therapeutics is headquartered in Miami, Florida.